Latest Healthcare News

Ansell Limited has updated its FY26 interim dividend details, confirming a USD 0.266 per share payout and setting the Dividend Reinvestment Plan price at USD 22.24 per share. The dividend will be paid in US dollars with an Australian dollar equivalent of AUD 0.3768 per share.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.

Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Freedom Care Group Holdings outlines a strategic recovery plan following the suspension of its securities and liquidation of its main operating subsidiary, aiming to restore shareholder value and regain ASX listing.

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.